Ioannis Felekos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ioannis Felekos has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Antonis N. Pavlidis
Cardiology Department, St. Thomas' Hospital, London. United Kingdom
3 shared publicationsConstantina Aggeli
1st Department of Cardiology, University of Athens, Hippokration Hospital, Athens, Greece
3 shared publications- Constantina Aggeli
First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece
3 shared publications Dimitrios Tousoulis
1st Cardiology Department, Hippokration Hospital, University of Athens Medical School, Athens, Greece
3 shared publicationsChristodoulos Stefanadis
First University Department of Cardiology, Hippokration Hospital, University of Athens, Athens, Greece
2 shared publications- Christodoulos Stefanadis
First Cardiology Clinic, School of Medicine, University of Athens, Athens, Greece
2 shared publications
Latest Publications
- Open Access
- 10 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1128
Coronary Microvascular Dysfunction and Vasospastic Angina—Pathophysiology, Diagnosis and Management Strategies
Coronary artery disease is one of the leading public health problems in the world in terms of mortality and economic burden from the disease. Traditionally, the focus of research and clinical pathways leading to the diagnosis and treatment of coronary artery disease was on the more common variant of the disease resulting from atherosclerosis in the epicardial coronary arteries. However, coronary microvasculature, representing the vast majority of the total heart circulation, has the greatest influence on overall coronary resistance and, therefore, blood flow. Coronary microvascular dysfunction (CMD), characterized by structural or functional abnormalities in the microvasculature, significantly impacts myocardial perfusion. Endothelial dysfunction results in inadequate coronary dilation during exercise or spontaneous spasm in the microvasculature or epicardial arteries. A significant proportion of people presenting for coronary angiography in the context of angina have unobstructed epicardial coronary arteries yet are falsely reassured about the benign nature of their condition. Meanwhile, increasing evidence indicates that patients diagnosed with CMD as well as vasospastic angina (VSA) face an increased risk of Major Adverse Cardiovascular Events (MACEs), including death. The aim of this review is to outline the current practice with regard to invasive and non-invasive methods of CMD and VSA diagnosis and assess the evidence supporting the existing treatment strategies. These include endotype-specific pharmacological therapies, a holistic approach to lifestyle modifications and risk factor management and novel non-pharmacological therapies. Furthermore, the review highlights critical gaps in research and suggests potential areas for future investigation, to improve understanding and management of these conditions.
- 10 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1128
Open AccessCoronary Microvascular Dysfunction and Vasospastic Angina—Pathophysiology, Diagnosis and Management Strategies
Coronary artery disease is one of the leading public health problems in the world in terms of mortality and economic burden from the disease. Traditionally, the focus of research and clinical pathways leading to the diagnosis and treatment of coronary artery disease was on the more common variant of the disease resulting from atherosclerosis in the epicardial coronary arteries. However, coronary microvasculature, representing the vast majority of the total heart circulation, has the greatest influence on overall coronary resistance and, therefore, blood flow. Coronary microvascular dysfunction (CMD), characterized by structural or functional abnormalities in the microvasculature, significantly impacts myocardial perfusion. Endothelial dysfunction results in inadequate coronary dilation during exercise or spontaneous spasm in the microvasculature or epicardial arteries. A significant proportion of people presenting for coronary angiography in the context of angina have unobstructed epicardial coronary arteries yet are falsely reassured about the benign nature of their condition. Meanwhile, increasing evidence indicates that patients diagnosed with CMD as well as vasospastic angina (VSA) face an increased risk of Major Adverse Cardiovascular Events (MACEs), including death. The aim of this review is to outline the current practice with regard to invasive and non-invasive methods of CMD and VSA diagnosis and assess the evidence supporting the existing treatment strategies. These include endotype-specific pharmacological therapies, a holistic approach to lifestyle modifications and risk factor management and novel non-pharmacological therapies. Furthermore, the review highlights critical gaps in research and suggests potential areas for future investigation, to improve understanding and management of these conditions.
- Open Access
- 29 November 2023
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 18, e29
Validation of the MIRACLE2 Score for Prognostication After Out-of-hospital Cardiac Arrest
Background: Out-of-hospital cardiac arrest (OHCA) is associated with very poor clinical outcomes. An optimal pathway of care is yet to be defined, but prognostication is likely to assist in the challenging decision-making required for treatment of this high-risk patient cohort. The MIRACLE2 score provides a simple method of neuro-prognostication but as yet it has not been externally validated. The aim of this study was therefore to retrospectively apply the score to a cohort of OHCA patients to assess the predictive ability and accuracy in the identification of neurological outcome. Methods: Retrospective data of patients identified by hospital coding, over a period of 18 months, were collected from a large tertiary-level cardiac centre with a mature, multidisciplinary OHCA service. MIRACLE2 score performance was assessed against three existing OHCA prognostication scores. Results: Patients with all-comer OHCA, of presumed cardiac origin, with and without evidence of ST-elevation MI (43.4% versus 56.6%, respectively) were included. Regardless of presentation, the MIRACLE2 score performed well in neuro-prognostication, with a low MIRACLE2 score (≤2) providing a negative predictive value of 94% for poor neurological outcome at discharge, while a high score (≥5) had a positive predictive value of 95%. A high MIRACLE2 score performed well regardless of presenting ECG, with 91% of patients receiving early coronary angiography having a poor outcome. Conclusion: The MIRACLE2 score has good prognostic performance and is easily applicable to cardiac-origin OHCA presentation at the hospital front door. Prognostic scoring may assist decision-making regarding early angiographic assessment.
- 29 November 2023
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 18, e29
Open AccessValidation of the MIRACLE2 Score for Prognostication After Out-of-hospital Cardiac Arrest
Background: Out-of-hospital cardiac arrest (OHCA) is associated with very poor clinical outcomes. An optimal pathway of care is yet to be defined, but prognostication is likely to assist in the challenging decision-making required for treatment of this high-risk patient cohort. The MIRACLE2 score provides a simple method of neuro-prognostication but as yet it has not been externally validated. The aim of this study was therefore to retrospectively apply the score to a cohort of OHCA patients to assess the predictive ability and accuracy in the identification of neurological outcome. Methods: Retrospective data of patients identified by hospital coding, over a period of 18 months, were collected from a large tertiary-level cardiac centre with a mature, multidisciplinary OHCA service. MIRACLE2 score performance was assessed against three existing OHCA prognostication scores. Results: Patients with all-comer OHCA, of presumed cardiac origin, with and without evidence of ST-elevation MI (43.4% versus 56.6%, respectively) were included. Regardless of presentation, the MIRACLE2 score performed well in neuro-prognostication, with a low MIRACLE2 score (≤2) providing a negative predictive value of 94% for poor neurological outcome at discharge, while a high score (≥5) had a positive predictive value of 95%. A high MIRACLE2 score performed well regardless of presenting ECG, with 91% of patients receiving early coronary angiography having a poor outcome. Conclusion: The MIRACLE2 score has good prognostic performance and is easily applicable to cardiac-origin OHCA presentation at the hospital front door. Prognostic scoring may assist decision-making regarding early angiographic assessment.
- 1 January 2022
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 34 (2) , E154-E155
Challenges in Primary PCI: How to Treat a Large Intracoronary Thrombus With TIMI 3 Flow?
A 52-year-old man presented acutely with inferior ST-segment elevation myocardial infarction (STEMI). The left coronary system was unobstructed. The right coronary artery had Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow throughout; however, angiography demonstrated a hazy oval filling defect proximally consistent with a large intracoronary thrombus.
- 1 January 2022
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 34 (2) , E154-E155
Challenges in Primary PCI: How to Treat a Large Intracoronary Thrombus With TIMI 3 Flow?
A 52-year-old man presented acutely with inferior ST-segment elevation myocardial infarction (STEMI). The left coronary system was unobstructed. The right coronary artery had Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow throughout; however, angiography demonstrated a hazy oval filling defect proximally consistent with a large intracoronary thrombus.
- 29 June 2021
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 30 (6) , 286-292
Acute Coronary Syndromes Due to Atherosclerotic Coronary Artery Disease in Young Patients
Young patients represent about 4–10% of the population presenting with acute coronary syndrome. In this focused mini-review, we highlight the data regarding acute coronary syndromes in young patients with atherosclerotic coronary artery disease. Differences in the underlying pathologies and pathophysiological mechanisms should yield to different clinical management and treatment strategies.
- 29 June 2021
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 30 (6) , 286-292
Acute Coronary Syndromes Due to Atherosclerotic Coronary Artery Disease in Young Patients
Young patients represent about 4–10% of the population presenting with acute coronary syndrome. In this focused mini-review, we highlight the data regarding acute coronary syndromes in young patients with atherosclerotic coronary artery disease. Differences in the underlying pathologies and pathophysiological mechanisms should yield to different clinical management and treatment strategies.
- 8 April 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 27 (8) , 1008-1014
PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low?
Diabetic patients are considered to be at high risk for the development of atherosclerotic disease. Management of hypercholesterolemia is of paramount importance to optimize cardiovascular outcomes in this subset of patients and statins are regarded as the mainstay of treatment. However, the recent advent of PCSK-9 inhibitors has provided a useful alternative in the management of dyslipidemia, especially when statins cannot be tolerated or when hypolipidemic targets cannot be achieved. In this review, we discuss current trends in their use, and we focus on their role in the management of diabetic dyslipidemia.
- 8 April 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 27 (8) , 1008-1014
PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low?
Diabetic patients are considered to be at high risk for the development of atherosclerotic disease. Management of hypercholesterolemia is of paramount importance to optimize cardiovascular outcomes in this subset of patients and statins are regarded as the mainstay of treatment. However, the recent advent of PCSK-9 inhibitors has provided a useful alternative in the management of dyslipidemia, especially when statins cannot be tolerated or when hypolipidemic targets cannot be achieved. In this review, we discuss current trends in their use, and we focus on their role in the management of diabetic dyslipidemia.
- 1 November 2020
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 21 (11) , 60-62
Acute Circumflex Occlusion After a Successful Mitral Valve Repair
- 1 November 2020
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 21 (11) , 60-62
Acute Circumflex Occlusion After a Successful Mitral Valve Repair
- 1 November 2019
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 20 (11) , 3-5
Spinal Hematoma Following Coronary Angioplasty: An Uncommon Complication
- 1 November 2019
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 20 (11) , 3-5
Spinal Hematoma Following Coronary Angioplasty: An Uncommon Complication
- 1 April 2018
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 19 (3) , 306-313
When everything else fails: High-pressure balloon for undilatable lesions
- 1 April 2018
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 19 (3) , 306-313
When everything else fails: High-pressure balloon for undilatable lesions
- 28 February 2018
- Published by Wiley in Echocardiography
- Vol. 35 (6) , 804-808
Global longitudinal strain and long‐term outcomes in asymptomatic extracardiac sarcoid patients with no apparent cardiovascular disease
Purpose: Global longitudinal strain (GLS) is increasingly accepted as a predictor of mortality in various clinical settings. This study tested the hypothesis that GLS is associated with increased event rate in patients with extracardiac sarcoidosis, who have no overt symptoms of cardiovascular disease and preserved ejection fraction (EF).Methods: We retrospectively studied 117 patients with extracardiac sarcoidosis and 45 age‐ and sex‐matched controls, who underwent comprehensive echocardiographic study, while GLS was measured by an offline speckle tracking algorithm. Patients who had signs and symptoms of cardiovascular disease at the time of the examination were excluded from the study. Patients were followed for an average of 57.1 months. Primary endpoint was defined as a composite endpoint of heart failure‐related hospitalizations, need for device therapy, arrhythmias, and all‐cause mortality.Results: The age of patients was 42 ± 6 years old (43 men). Events were recorded in 10 patients (8.5%). Tissue Doppler revealed E/Em 7.9 ± 3.5, while EF was 54.2 ± 3.5%. Global longitudinal strain was 14.4 ± 3%, and a cutoff value ≤−13.6% for GLS was considered more associated with adverse outcomes (AUC 0.84). After adjustment for multiple potential confounders (age, gender, hypertension, diabetes, E/Em, and EF), GLS remained strongly associated with adverse outcomes (HR 0.8, 0.63 to 0.98 95% C.I, P = .04).Conclusions: In conclusion, among patients with extracardiac sarcoidosis and no symptoms of cardiovascular disease, even when EF is preserved, GLS seems to be strongly associated with adverse future events.
- 28 February 2018
- Published by Wiley in Echocardiography
- Vol. 35 (6) , 804-808
Global longitudinal strain and long‐term outcomes in asymptomatic extracardiac sarcoid patients with no apparent cardiovascular disease
Purpose: Global longitudinal strain (GLS) is increasingly accepted as a predictor of mortality in various clinical settings. This study tested the hypothesis that GLS is associated with increased event rate in patients with extracardiac sarcoidosis, who have no overt symptoms of cardiovascular disease and preserved ejection fraction (EF).Methods: We retrospectively studied 117 patients with extracardiac sarcoidosis and 45 age‐ and sex‐matched controls, who underwent comprehensive echocardiographic study, while GLS was measured by an offline speckle tracking algorithm. Patients who had signs and symptoms of cardiovascular disease at the time of the examination were excluded from the study. Patients were followed for an average of 57.1 months. Primary endpoint was defined as a composite endpoint of heart failure‐related hospitalizations, need for device therapy, arrhythmias, and all‐cause mortality.Results: The age of patients was 42 ± 6 years old (43 men). Events were recorded in 10 patients (8.5%). Tissue Doppler revealed E/Em 7.9 ± 3.5, while EF was 54.2 ± 3.5%. Global longitudinal strain was 14.4 ± 3%, and a cutoff value ≤−13.6% for GLS was considered more associated with adverse outcomes (AUC 0.84). After adjustment for multiple potential confounders (age, gender, hypertension, diabetes, E/Em, and EF), GLS remained strongly associated with adverse outcomes (HR 0.8, 0.63 to 0.98 95% C.I, P = .04).Conclusions: In conclusion, among patients with extracardiac sarcoidosis and no symptoms of cardiovascular disease, even when EF is preserved, GLS seems to be strongly associated with adverse future events.
- Open Access
- 1 November 2016
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 57 (6) , 445-448
Lactobacillus rhamnosus endocarditis: An unusual culprit in a patient with Barlow's disease
- 1 November 2016
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 57 (6) , 445-448
Open AccessLactobacillus rhamnosus endocarditis: An unusual culprit in a patient with Barlow's disease